Table 4.
Patient use of acute and preventive migraine treatment in the 6 months pre- and post-erenumab stratified by persistence
| Pre-erenumab | Post-erenumab | |||||
|---|---|---|---|---|---|---|
| All (N = 4437) | Erenumab persistent (N = 1853) | Erenumab non-persistent (N = 2584) | All (N = 4437) | Erenumab persistent (N = 1853) | Erenumab non-persistent (N = 2584) | |
| Number of acute medications used, n (%) | ||||||
| 0 | 402 (9.1) | 146 (7.9) | 256 (9.9) | 610 (13.7) | 242 (13.1) | 368 (14.2) |
| 1 | 1294 (29.2) | 554 (29.9) | 740 (28.6) | 1373 (30.9) | 593 (32.0) | 780 (30.2) |
| 2 | 114 (25.8) | 488 (26.3) | 656 (25.4) | 1077 (24.3) | 446 (24.1) | 631 (24.4) |
| 3 | 777 (17.5) | 332 (17.9) | 445 (17.2) | 674 (15.2) | 284 (15.3) | 390 (15.1) |
| 4 | 404 (9.1) | 153 (8.3) | 251 (9.7) | 355 (8.0) | 162 (8.7) | 193 (7.5) |
| 5+ | 416 (9.4) | 180 (9.7) | 236 (9.1) | 348 (7.8) | 126 (6.8) | 222 (8.6) |
| Type of acute medication used, n (%) | ||||||
| Triptans | 3037 (68.4) | 1342 (72.4) | 1695 (65.6) | 2712 (61.1) | 1196 (64.5) | 1516 (58.7) |
| Ergotamines | 214 (4.8) | 90 (4.9) | 124 (4.8) | 168 (3.8) | 65 (3.5) | 103 (4.0) |
| NSAIDs | 1646 (37.1) | 685 (37.0) | 961 (37.2) | 1517 (34.2) | 627 (33.8) | 890 (34.4) |
| Opioids | 1682 (37.9) | 680 (36.7) | 1002 (38.8) | 1699 (38.3) | 688 (37.1) | 1011 (39.1) |
| 2+ opioid claims | 1150 (25.9) | 457 (24.7) | 693 (26.8) | 1125 (25.4) | 456 (24.6) | 669 (25.9) |
| Analgesicsa | 825 (18.6) | 329 (17.8) | 496 (19.2) | 741 (16.7) | 280 (15.1) | 461 (17.8) |
| Number of preventive medications used, n (%) | ||||||
| 0 | 564 (12.7) | 235 (12.7) | 329 (12.7) | 878 (19.8) | 402 (21.7) | 476 (18.4) |
| 1 | 1131 (25.5) | 515 (27.8) | 616 (23.8) | 1235 (27.8) | 528 (28.5) | 707 (27.4) |
| 2 | 1195 (26.9) | 491 (26.5) | 704 (27.2) | 1110 (25.0) | 461 (24.9) | 649 (25.1) |
| 3 | 804 (18.1) | 312 (16.8) | 492 (19.0) | 673 (15.2) | 260 (14.0) | 413 (16.0) |
| 4 | 451 (10.2) | 186 (10.0) | 265 (10.3) | 334 (7.5) | 138 (7.4) | 196 (7.6) |
| 5+ | 292 (6.6) | 114 (6.2) | 178 (6.9) | 207 (4.7) | 64 (3.5) | 143 (5.5) |
| Type of preventive medication used, n (%) | ||||||
| Anticonvulsant | 2249 (50.7) | 908 (49.0) | 1341 (51.9) | 1863 (42.0) | 735 (39.7) | 1128 (43.7) |
| Antidepressant | 2206 (49.7) | 879 (47.4) | 1327 (51.4) | 2001 (45.1) | 779 (42.0) | 1222 (47.3) |
| Antihypertensive | 1540 (34.7) | 642 (34.6) | 898 (34.8) | 1335 (30.1) | 542 (29.2) | 793 (30.7) |
| Botulinum toxin | 1302 (29.3) | 575 (31.0) | 727 (28.1) | 1048 (23.6) | 452 (24.4) | 596 (23.1) |
| Anti-CGRP (excluding erenumab) | 0 (0.0) | 0 (0) | 0 (0) | 552 (12.4) | 43 (2.3) | 509 (19.7) |
| Otherb | 744 (16.8) | 277 (14.9) | 467 (18.1) | 690 (15.6) | 249 (13.4) | 441 (17.1) |
| Associated costs, mean (SD) | ||||||
| Acute migraine treatment costs | $1206 ($8164) | $1463 ($12,298) | $1021 ($2437) | $1054 ($7214) | $1245 ($10,845) | $916 ($2235) |
| Preventive migraine treatment costs (excluding anti-CGRPs) | $1321 ($2028) | $1346 ($2034) | $1303 ($2024) | $1124 ($1959) | $1120 ($1908) | $1127 ($1995) |
| Total acute and preventive migraine treatment costs (excluding anti-CGRPs) | $2526 ($8453) | $2809 ($12,470) | $2324 ($3334) | $2178 ($7540) | $2365 ($11,028) | $2043 ($3225) |
| Anti-CGRP costs (excluding erenumab) | $0 ($0) | $0 ($0) | $0 ($0) | $171 ($6) | $24 ($2) | $276 ($7) |
aNon-NSAID/non-opioid analgesics
bOther agents prescribed for migraine prevention such as memantine, milnaciprin, etc.